Orgenesis to Sponsor and Present at ESGCT 20th Anniversary Congress
Orgenesis Inc. (ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce its participation and sponsorship at the European Society of Gene & Cell Therapy (“ESGCT”) 20th Anniversary Congress, to be held October 26-29, 2012 in Versailles, France.
Prof. Sarah Ferber, Chief Science Officer of Orgenesis, will serve as chair of the Adult Cell Reprogramming section and will give a presentation entitled “Transdifferentiation: autologous cell replacement therapy.”
“We are proud to support this year's ESGCT congress and to be part of the global effort to advance the science and promise of gene and cell therapy,” commented Jacob BenArie, President and CEO of Orgenesis. “Our participation also provides us with an opportunity to update experts in the field on our research directed towards advancing a better treatment for diabetes.”
The European Society of Gene and Cell Therapy promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
About Orgenesis Inc.
Orgenesis (OTCBB: ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to retain key employees and our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
On Behalf of the Board
Vered Caplan, Chairperson